Brief: Sprint Bioscience Operating Loss SEK 8.4 Mln
25/11/2025 06:44
Nov 25 (Reuters) - Sprint Bioscience AB SPRINT.ST: OPERATING RESULT FOR Q3 WAS -8.4 MSEK Source text: ID:nMFN6PjTrc Further company coverage: SPRINT.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Sprint Bioscience AB
See all newsBrief: Sprint Bioscience And Max IV Receive Funding From Vinnova
Brief: Sprint Bioscience Q2 Loss After Tax SEK 16.2 Million
Brief: Sprint Bioscience Announces Deal With Lilly Tunelab
Brief: Sprint Bioscience Partners With Lilly Tunelab For Drug Development
Brief: Sprint Bioscience Q1 Operating Loss SEK 14.3 Mln